Picture of Global Human Microbiome Market Forecast 2018-2026

Global Human Microbiome Market Forecast 2018-2026

August 2018


The Global Human microbiome market is anticipated to grow at a CAGR of 22.41% between 2022 and 2026. The human microbiome represents a significant commercial opportunity for the life sciences sector. A wide range of scientific studies have clearly demonstrated the role of the microbiome in the pathogenesis of a variety of mainstream diseases. The Human Microbiome market is primarily driven by the following factors:

  • Rising prevalence of precision medicines
  • Focus on early disease detection and diagnosis
  • Growing prevalence of chronic diseases

The important driver increasing growth in the Global Human Microbiome Market is the rising prevalence of precision medicines. Precision medicine allows patients to enrich the effectiveness of the drug on patients. Precision medicine uses diagnostic tests to recognize specific medical treatments and procedures. These diagnostic tests are then joint with the individual’s medical records, values, and circumstances, which allow the doctors to develop targeted treatment and prevention plans.

The commercial role of microbiota in various diseases of Human Microbiome Market is used extensively for various diseases treatment. Recent research in microbiome field has indicated the role of commensal microbiota (e.g., yeast, fungi, bacteria) in the genesis and progression of cancer as well. Obesity is the single most important risk factor for atherosclerotic cardiovascular disease, type 2 diabetes, Alzheimer’s disease non-alcoholic fatty liver disease, and certain types of cancers. More than 500 million people across the world suffer from type 2 diabetes. Ulcerative colitis affects solitary colon, while the inflammatory configuration includes superficial inflammation commencement at the anal verge, encompassing proximally over the colon in an incessant method. Crohn’s disease affects several sections of the gastrointestinal tract (from the mouth to anus). Clostridium difficle is an obligate anaerobe bacterium that causes C. difficle infection, which affects the gastrointestinal tract. Lactose intolerance is a common gastrointestinal condition that often causes painful and embarrassing symptoms from the consumption of dairy products. Hepatic encephalopathy (HE) is a complication of hepatic cirrhosis.

Barriers to early detection and diagnosis and lack of technical expertise are the major factors hindering the Human microbiome market. One of the major barriers in the early detection and diagnosis of the disease is sample collection. For instance, collections of the faecal sample which are used to study gut microbiome. The research and training institutions for human microbiomes are substantially less.  Thus, lack of technical expertise required to assemble and study large-scale microbiome datasets is restraining the market growth of Global Human Microbiome Market.

The Global Human microbiome market segments include applications, products, and diseases.

Applications are segmented into:

  • Drugs
  • Diagnostics

Products are segmented into:

  • Probiotics
  • Foods
  • Prebiotics
  • Medical foods
  • Diagnostic device
  • Drugs
  • Other products

Diseases are segmented into:

  • Cancer
  • Obesity
  • Type 2 diabetes
  • Ulcerative colitis
  • Crohn’s disease
  • Difficle infection
  • Lactose intolerance
  • Dental caries
  • Recurrent bacterial vaginosis and UTI
  • Skin disorders
  • Hyperoxaluria
  • Celiac disease
  • Urea cycle disorder
  • Phenylketonuria
  • Non-alcoholic steatohepatitis
  • Hepatic encephalopathy

This report covers the present market conditions and the growth prospects of the Global Human Microbiomes Market for 2018-2026 and considered the revenue generated through the sales of Human microbiomes for applications, products, and diseases to calculate the market size, by considering 2017 as the base year.

Geographically, the global Human microbiomes market has been segmented on the basis of four major regions, which include:

  • North America: The U.S. & Canada
  • Asia-Pacific: China, India, Japan, South Korea, Australia & Rest of APAC
  • Europe: The UK, France, Germany, Italy, Spain & Rest of Europe
  • Rest of World: Latin America & Middle East and Africa

The Human microbiome market in North America is expected to hold the largest share by 2026 on account of the growing funding and research and development activities by companies and research institutes. The United States is a major country in the North American human microbiome market. The presence of a large number of players who are adopting various initiatives such as investment in research and development for the development of the new therapeutic area for microbiome to prevent health issues such as irritable bowel syndrome, immune diseases, etc. is further contributing to the market. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Human microbiome market. Human microbiome in on a surging trend in the Asia-Pacific region owing to rising government funding in precision medicine and the emergence of numerous initiatives to develop human microbiome in countries such as China, Japan. These initiatives aim to optimize the methods for the assessment of the effect of the gut microbiome on human health through the standardization of protocols and procedures.

The Human microbiome market is segmented on the basis of Applications which are sub-divided into Drugs & Diagnostics and also is also segmented on the basis of Products which are sub-divided into Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs & other products. Microbiome in Drugs helps in the development of novel non-prescription therapies that have the ability to improve the health status of the person by networking with the human microbiome in particular ways. Microbiomes are majorly used to measure and detect the concentration of biomarkers substances in the blood such as glucose, cholesterol, creatine kinase, cortisol, etc. that can help detect infection or disease. Probiotics are live microorganisms that include bacteria and yeast, which are good for health, especially for the digestive system. Prebiotic refers to a specialized plant fibre that positively nurtures the good bacteria that are already present in the colon of the large bowel. Microbiota or microbiome plays a significant role in the effectiveness of therapeutic compounds. It provides a major source of reductive metabolizing capability.

The major market players in the GLOBAL HUMAN MICROBIOME market are:


Company Profiles covers analysis of important players.

AvidBiotics is a privately held company developing a portfolio of therapeutic proteins targeting bacterial diseases and cancer. AvidBiotics has two platforms for the development of protein therapeutics: Avidocin proteins & MicAbody proteins. Another company, 4D Pharma,  is a U.K.-based company founded in 2014 that is developing a class of molecules called live biotherapeutics. Live biotherapeutics are strains of gut commensal bacteria that are isolated from healthy human donors.

Key Findings of the Global Human microbiome market:

  • North America is the global leader in human microbiome market
  • Probiotics product are majorly used
  • Usage of personalized medicines is increasing